脂联素
肺
纤维化
刚度
成纤维细胞
癌症研究
细胞生物学
化学
医学
内分泌学
内科学
生物
材料科学
复合材料
肥胖
生物化学
体外
胰岛素抵抗
作者
Júlia Németh,Wioletta Skrońska-Wąsek,Sophie Keppler,Annika Schundner,Alexander Groß,Tanja Schönberger,Karsten Quast,Karim C. El Kasmi,Clemens Ruppert,Andreas Guenther,Manfred Frick
出处
期刊:American Journal of Physiology-lung Cellular and Molecular Physiology
[American Physiological Society]
日期:2024-08-06
卷期号:327 (4): L487-L502
被引量:2
标识
DOI:10.1152/ajplung.00037.2024
摘要
Idiopathic pulmonary fibrosis (IPF) is a progressive, irreversible respiratory disease with limited therapeutic options. A hallmark of IPF is excessive fibroblast activation and extracellular matrix (ECM) deposition. The resulting increase in tissue stiffness amplifies fibroblast activation and drives disease progression. Dampening stiffness-dependent activation of fibroblasts could slow disease progression. We performed an unbiased, next-generation sequencing (NGS) screen to identify signaling pathways involved in stiffness-dependent lung fibroblast activation. Adipocytokine signaling was downregulated in primary lung fibroblasts (PFs) cultured on stiff matrices. Re-activating adipocytokine signaling with adiponectin suppressed stiffness-dependent activation of human PFs. Adiponectin signaling depended on CDH13 expression and p38 mitogen-activated protein kinase gamma (p38MAPKγ) activation. CDH13 expression and p38MAPKγ activation were strongly reduced in lungs from IPF donors. Our data suggest that adiponectin-signaling via CDH13 and p38MAPKγ activation suppresses profibrotic activation of fibroblasts in the lung. Targeting of the adiponectin signaling cascade may provide therapeutic benefits in IPF.
科研通智能强力驱动
Strongly Powered by AbleSci AI